tetano
Editor, Senior Moderator
Clin Exp Immunol. 2019 Oct 31. doi: 10.1111/cei.13395. [Epub ahead of print] [h=1]Differences in nasal IgA responses to influenza vaccine strains after Live Attenuated Influenza Vaccine (LAIV) immunisation in children.[/h]
Turner PJ[SUP]1,[/SUP][SUP]2[/SUP], Abdulla AF[SUP]3[/SUP], Cole ME[SUP]3[/SUP], Javan RR[SUP]3[/SUP], Gould V[SUP]3[/SUP], O'Driscoll ME[SUP]4[/SUP], Southern J[SUP]2[/SUP], Zambon M[SUP]2[/SUP], Miller E[SUP]2[/SUP], Andrews NJ[SUP]2[/SUP], H?schler K[SUP]2[/SUP], Tregoning JS[SUP]3[/SUP].
[h=3]Author information[/h] 1 National Heart and Lung Institute, Imperial College London, London, W2 1PG. 2 Public Health England (Colindale), London, UK. 3 Department of Infectious Disease, St Mary's Campus, Imperial College, London, W2 1PG. 4 Infectious Diseases Epidemiology, St Mary's Campus, Imperial College, London, W2 1PG.
[h=3]Abstract[/h] Different vaccine strains included in the Live Attenuated Influenza Vaccine (LAIV) have variable efficacy. The reasons for this are not clear and may include differences in immunogenicity. We report a phase IV open-label study on the immunogenicity of a single dose of quadrivalent LAIV (Fluenz™ Tetra) in children during the 2015/16 season, to investigate the antibody responses to different strains. Eligible children were enrolled to receive LAIV; nasal samples were collected before and approximately 4 weeks after immunisation. There was a significant increase in nasal IgA to the H3N2, B/Victoria lineage (B/Brisbane) and B/Yamagata lineage (B/Phuket) components, but not to the H1N1 component. The fold change in nasal IgA response was inversely proportional to the baseline nasal IgA titre for H1N1, H3N2 and B/Brisbane. We investigated possible associations that may explain baseline nasal IgA, including age and prior vaccination status, but found different patterns for different antigens, suggesting the response is multi-factorial. Overall, we observed differences in immune responses to different viral strains included in the vaccine, the reasons for this require further investigation.
? 2019 British Society for Immunology.
[h=4]KEYWORDS:[/h] Children; Influenza; Nasal; Public Health; Vaccine
PMID: 31670841 DOI: 10.1111/cei.13395
Turner PJ[SUP]1,[/SUP][SUP]2[/SUP], Abdulla AF[SUP]3[/SUP], Cole ME[SUP]3[/SUP], Javan RR[SUP]3[/SUP], Gould V[SUP]3[/SUP], O'Driscoll ME[SUP]4[/SUP], Southern J[SUP]2[/SUP], Zambon M[SUP]2[/SUP], Miller E[SUP]2[/SUP], Andrews NJ[SUP]2[/SUP], H?schler K[SUP]2[/SUP], Tregoning JS[SUP]3[/SUP].
[h=3]Author information[/h] 1 National Heart and Lung Institute, Imperial College London, London, W2 1PG. 2 Public Health England (Colindale), London, UK. 3 Department of Infectious Disease, St Mary's Campus, Imperial College, London, W2 1PG. 4 Infectious Diseases Epidemiology, St Mary's Campus, Imperial College, London, W2 1PG.
[h=3]Abstract[/h] Different vaccine strains included in the Live Attenuated Influenza Vaccine (LAIV) have variable efficacy. The reasons for this are not clear and may include differences in immunogenicity. We report a phase IV open-label study on the immunogenicity of a single dose of quadrivalent LAIV (Fluenz™ Tetra) in children during the 2015/16 season, to investigate the antibody responses to different strains. Eligible children were enrolled to receive LAIV; nasal samples were collected before and approximately 4 weeks after immunisation. There was a significant increase in nasal IgA to the H3N2, B/Victoria lineage (B/Brisbane) and B/Yamagata lineage (B/Phuket) components, but not to the H1N1 component. The fold change in nasal IgA response was inversely proportional to the baseline nasal IgA titre for H1N1, H3N2 and B/Brisbane. We investigated possible associations that may explain baseline nasal IgA, including age and prior vaccination status, but found different patterns for different antigens, suggesting the response is multi-factorial. Overall, we observed differences in immune responses to different viral strains included in the vaccine, the reasons for this require further investigation.
? 2019 British Society for Immunology.
[h=4]KEYWORDS:[/h] Children; Influenza; Nasal; Public Health; Vaccine
PMID: 31670841 DOI: 10.1111/cei.13395